248 related articles for article (PubMed ID: 23665339)
21. Identification of GLA/SE as an effective adjuvant for the induction of robust humoral and cell-mediated immune responses to EBV-gp350 in mice and rabbits.
Heeke DS; Lin R; Rao E; Woo JC; McCarthy MP; Marshall JD
Vaccine; 2016 May; 34(23):2562-9. PubMed ID: 27085175
[TBL] [Abstract][Full Text] [Related]
22. The Epstein-Barr virus (EBV) major envelope glycoprotein gp350/220-specific antibody reactivities in the sera of patients with different EBV-associated diseases.
Xu J; Ahmad A; Blagdon M; D'Addario M; Jones JF; Dolcetti R; Vaccher E; Prasad U; Menezes J
Int J Cancer; 1998 Oct; 79(5):481-6. PubMed ID: 9761116
[TBL] [Abstract][Full Text] [Related]
23. Expression and immunogenic characterization of recombinant gp350 for developing a subunit vaccine against Epstein-Barr virus.
Wang M; Jiang S; Han Z; Zhao B; Wang L; Zhou Z; Wang Y
Appl Microbiol Biotechnol; 2016 Feb; 100(3):1221-1230. PubMed ID: 26433969
[TBL] [Abstract][Full Text] [Related]
24. A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice.
Ogembo JG; Muraswki MR; McGinnes LW; Parcharidou A; Sutiwisesak R; Tison T; Avendano J; Agnani D; Finberg RW; Morrison TG; Fingeroth JD
J Transl Med; 2015 Feb; 13():50. PubMed ID: 25885535
[TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding.
Busse C; Feederle R; Schnölzer M; Behrends U; Mautner J; Delecluse HJ
J Virol; 2010 Jan; 84(2):1139-47. PubMed ID: 19889766
[TBL] [Abstract][Full Text] [Related]
26. Binding of the endogenously expressed Epstein-Barr virus (EBV) envelope glycoprotein gp350 with the viral receptor masks the major EBV-neutralizing epitope and affects gp350-specific ADCC.
Khyatti M; Ahmad A; Blagdon M; Frade R; Menezes J
J Leukoc Biol; 1998 Aug; 64(2):192-7. PubMed ID: 9715258
[TBL] [Abstract][Full Text] [Related]
27. Differences in the Epstein-Barr Virus gp350 IgA Antibody Response Are Associated With Increased Risk for Coinfection With a Second Strain of Epstein-Barr Virus.
Smith NA; Baresel PC; Jackson CL; Ogolla S; Toko EN; Heit S; Piriou E; Sumba OP; Middeldorp JM; Colborn KL; Rochford R
J Infect Dis; 2019 Feb; 219(6):955-963. PubMed ID: 30312417
[TBL] [Abstract][Full Text] [Related]
28. Establishment and characterization of Epstein-Barr virus gp350-expressing transfected human lymphoid (Raji) cell clones.
Khyatti M; Patel PC; Menezes J
Int J Cancer; 1991 Jun; 48(4):591-7. PubMed ID: 1646179
[TBL] [Abstract][Full Text] [Related]
29. Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults.
Moutschen M; Léonard P; Sokal EM; Smets F; Haumont M; Mazzu P; Bollen A; Denamur F; Peeters P; Dubin G; Denis M
Vaccine; 2007 Jun; 25(24):4697-705. PubMed ID: 17485150
[TBL] [Abstract][Full Text] [Related]
30. Antibodies to gp350/220 enhance the ability of Epstein-Barr virus to infect epithelial cells.
Turk SM; Jiang R; Chesnokova LS; Hutt-Fletcher LM
J Virol; 2006 Oct; 80(19):9628-33. PubMed ID: 16973566
[TBL] [Abstract][Full Text] [Related]
31. Epstein-Barr Virus gp350 Can Functionally Replace the Rhesus Lymphocryptovirus Major Membrane Glycoprotein and Does Not Restrict Infection of Rhesus Macaques.
Herrman M; Mühe J; Quink C; Wang F
J Virol; 2016 Feb; 90(3):1222-30. PubMed ID: 26559839
[TBL] [Abstract][Full Text] [Related]
32. CD21 (Complement Receptor 2) Is the Receptor for Epstein-Barr Virus Entry into T Cells.
Smith NA; Coleman CB; Gewurz BE; Rochford R
J Virol; 2020 May; 94(11):. PubMed ID: 32238579
[TBL] [Abstract][Full Text] [Related]
33. Vesicular Stomatitis Virus-Based Epstein-Barr Virus Vaccines Elicit Strong Protective Immune Responses.
Kong XW; Zhang X; Bu GL; Xu HQ; Kang YF; Sun C; Zhu QY; Ma RB; Liu Z; Zeng YX; Zeng MS; Hu ZL
J Virol; 2022 May; 96(9):e0033622. PubMed ID: 35404082
[TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity.
Khyatti M; Patel PC; Stefanescu I; Menezes J
J Virol; 1991 Feb; 65(2):996-1001. PubMed ID: 1846213
[TBL] [Abstract][Full Text] [Related]
35. Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice.
Dasari V; McNeil LK; Beckett K; Solomon M; Ambalathingal G; Thuy TL; Panikkar A; Smith C; Steinbuck MP; Jakubowski A; Seenappa LM; Palmer E; Zhang J; Haqq CM; DeMuth PC; Khanna R
Nat Commun; 2023 Aug; 14(1):4371. PubMed ID: 37553346
[TBL] [Abstract][Full Text] [Related]
36. A phase I trial of epstein-barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation.
Rees L; Tizard EJ; Morgan AJ; Cubitt WD; Finerty S; Oyewole-Eletu TA; Owen K; Royed C; Stevens SJ; Shroff RC; Tanday MK; Wilson AD; Middeldorp JM; Amlot PL; Steven NM
Transplantation; 2009 Oct; 88(8):1025-9. PubMed ID: 19855249
[TBL] [Abstract][Full Text] [Related]
37. EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: potential use of gp350/gp85 CTL epitopes for vaccine design.
Khanna R; Sherritt M; Burrows SR
J Immunol; 1999 Mar; 162(5):3063-9. PubMed ID: 10072559
[TBL] [Abstract][Full Text] [Related]
38. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
[TBL] [Abstract][Full Text] [Related]
39. Epstein-Barr Virus and its glycoprotein-350 upregulate IL-6 in human B-lymphocytes via CD21, involving activation of NF-kappaB and different signaling pathways.
D'Addario M; Libermann TA; Xu J; Ahmad A; Menezes J
J Mol Biol; 2001 May; 308(3):501-14. PubMed ID: 11327783
[TBL] [Abstract][Full Text] [Related]
40. Exosomes containing glycoprotein 350 released by EBV-transformed B cells selectively target B cells through CD21 and block EBV infection in vitro.
Vallhov H; Gutzeit C; Johansson SM; Nagy N; Paul M; Li Q; Friend S; George TC; Klein E; Scheynius A; Gabrielsson S
J Immunol; 2011 Jan; 186(1):73-82. PubMed ID: 21106852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]